CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Brain and Behavior"
DOI: 10.1002/brb3.1215
Abstract: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the… read more here.
Keywords: migraine; meta analysis; chronic migraine; preventive treatment ... See more keywords
Refractory migraine profile in CGRP‐monoclonal antibodies scenario
Sign Up to like & getrecommendations! Published in 2021 at "Acta Neurologica Scandinavica"
DOI: 10.1111/ane.13472
Abstract: Refractory migraine (Ref‐M) represents a conundrum that headache experts have to face with. We aim to investigate whether a peculiar profile may characterize patients with Ref‐M according to 2020 European Headache Federation criteria. Furthermore, to… read more here.
Keywords: migraine; profile cgrp; refractory migraine; migraine profile ... See more keywords
“Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2023 at "Cephalalgia"
DOI: 10.1177/03331024231161261
Abstract: Background A new migraine prevention, CGRP monoclonal antibodies (mAbs), is injectable on a monthly or quarterly basis. In clinical practice, some patients reported that drug effectiveness does not last until the upcoming scheduled injection, a… read more here.
Keywords: meta analysis; cgrp monoclonal; effect; migraine prevention ... See more keywords